Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Acquisition Of Compound BCR-ABL1 Alleles As A Mechanism Of Resistance To Ponatinib In Chronic Myeloid Leukemia

Don L Gibbons, MD, PhD, Sabrina Pricl, Paola Posocco, PhD, Erik Laurini, PhD, Maurizio Fermeglia, Moshe Talpaz, MD, Jorge E. Cortes, MD, Nicholas J. Donato, PhD, Alfonso Quintas-Cardama, MD

Blood (2013) 122 (21): 853.

https://doi.org/10.1182/blood.V122.21.853.853

Published: 2013

Journal Articles

Usp9x Silencing and Enzyme Inhibition Suppress Myeloma Cell Survival and in Vivo Tumor Growth.

Luke F. Peterson, PhD, Hanshi Sun, PhD, Yihong Liu, PhD, Malathi Kandarpa, PhD, Diane Giannola, Jessica Mercer, PhD, Hollis D. Showalter, Ph.D., Andrzej Jakubowiak, MD, PhD, Moshe Talpaz, MD, Nicholas J. Donato, PhD

Blood (2012) 120 (21): 2936.

https://doi.org/10.1182/blood.V120.21.2936.2936

Published: 2012

Journal Articles

Activity of ABL Kinase Inhibitors in Two Distinct Models of Imatinib Resistance.

Nicholas J. Donato, PhD, Ji Wu, M.D., William Bornmann, Ph.D., Moshe Talpaz, M.D.

Blood (2006) 108 (11): 4819.

https://doi.org/10.1182/blood.V108.11.4819.4819

Published: 2006

Journal Articles

Lyn Kinase Alters Gab2 Phosphorylation and c-Cbl Protein Levels To Regulate Imatinib Sensitivity and Survival of Chronic Myelogenous Leukemia Cells.

Ji Wu, MD, Feng Meng, M.D., Moshe Talpaz, M.D., Nicholas J. Donato, PhD

Blood (2006) 108 (11): 2132.

https://doi.org/10.1182/blood.V108.11.2132.2132

Published: 2006

Journal Articles

Antitumor Activity and Mechanism of Action of a Novel Stat3 Inhibitor, WP1066, Against Human B-Cell Non-Hodgkin’s Lymphoma and Multiple Myeloma.

Ling-Yuan Kong, MD, PhD, Vaibhav Kapuria, Geoffrey Bartholomeusz, PhD, Moshe Talpaz, MD, Waldemar Priebe, PhD, Nicholas J. Donato, PhD

Blood (2005) 106 (11): 1489.

https://doi.org/10.1182/blood.V106.11.1489.1489

Published: 2005

Journal Articles

Constitutive Activation of SRC-Family Kinases in Chronic Myelogenous Leukemia Patients Resistant to Imatinib Mesylate in the Absence of BCR-ABL Mutations: A Rationale for Use of SRC/ABL Dual Kinase Inhibitor-Based Therapy.

Nicholas J. Donato, PhD, Ji Wu, MD, Ling-Yuan Kong, MD, PhD, Feng Meng, MD, Francis Lee, PhD, Moshe Talpaz, MD

Blood (2005) 106 (11): 1087.

https://doi.org/10.1182/blood.V106.11.1087.1087

Published: 2005

Journal Articles

Targeting BCR-ABL and Its Downstream Signaling Cascade as Therapy for Chronic Myelogenous Leukemia.

Nicholas J. Donato, PhD, Ji Wu, MD, Ling Y. Kong, MD, PhD, Feng Meng, MD, Waldemar Priebe, PhD, Moshe Talpaz, MD

Blood (2004) 104 (11): 2964.

https://doi.org/10.1182/blood.V104.11.2964.2964

Published: 2004

NARROW

Acquisition Of Compound BCR-ABL1 Alleles As A Mechanism Of Resistance To Ponatinib In Chronic Myeloid Leukemia

Usp9x Silencing and Enzyme Inhibition Suppress Myeloma Cell Survival and in Vivo Tumor Growth.

Activity of ABL Kinase Inhibitors in Two Distinct Models of Imatinib Resistance.

Lyn Kinase Alters Gab2 Phosphorylation and c-Cbl Protein Levels To Regulate Imatinib Sensitivity and Survival of Chronic Myelogenous Leukemia Cells.

Antitumor Activity and Mechanism of Action of a Novel Stat3 Inhibitor, WP1066, Against Human B-Cell Non-Hodgkin’s Lymphoma and Multiple Myeloma.

Constitutive Activation of SRC-Family Kinases in Chronic Myelogenous Leukemia Patients Resistant to Imatinib Mesylate in the Absence of BCR-ABL Mutations: A Rationale for Use of SRC/ABL Dual Kinase Inhibitor-Based Therapy.

Targeting BCR-ABL and Its Downstream Signaling Cascade as Therapy for Chronic Myelogenous Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Acquisition Of Compound BCR-ABL1 Alleles As A Mechanism Of Resistance To Ponatinib In Chronic Myeloid Leukemia

Usp9x Silencing and Enzyme Inhibition Suppress Myeloma Cell Survival and in Vivo Tumor Growth.

Activity of ABL Kinase Inhibitors in Two Distinct Models of Imatinib Resistance.

Lyn Kinase Alters Gab2 Phosphorylation and c-Cbl Protein Levels To Regulate Imatinib Sensitivity and Survival of Chronic Myelogenous Leukemia Cells.

Antitumor Activity and Mechanism of Action of a Novel Stat3 Inhibitor, WP1066, Against Human B-Cell Non-Hodgkin’s Lymphoma and Multiple Myeloma.

Constitutive Activation of SRC-Family Kinases in Chronic Myelogenous Leukemia Patients Resistant to Imatinib Mesylate in the Absence of BCR-ABL Mutations: A Rationale for Use of SRC/ABL Dual Kinase Inhibitor-Based Therapy.

Targeting BCR-ABL and Its Downstream Signaling Cascade as Therapy for Chronic Myelogenous Leukemia.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only